Home>Topics>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Moody's expects an increasing number of healthcare companies to succumb to peer pressure and start paying dividends to satiate investor appetite "for immediate, stable income amid today's low ...

    Headlines

    Mon, 14 May 2012

    appetite "for immediate, stable income amid today's low interest rate environment." Names Moody's throws out are Lab Corp. ( LH ), Life Tech ( LIFE ), Celgene ( CELG ), Biogen ( BIIB ) and CareFusion ( CFN ). Post your comment!

  2. New Morningstar Analyst Report - Teva Pharmaceutical Industries, Ltd.

    Stock Reports

    Mon, 14 May 2012

    endpoints in its second Phase III trial and appears to be less effective than competing compounds from Novartis and Biogen Idec .Teva faces considerable competition from low-cost producers in India and China. Aggressive entry pricing could

  3. New Morningstar Analyst Report - Merck

    Stock Reports

    Fri, 11 May 2012

    veteran Judy Lewent, who announced her retirement in early 2007. Kellogg's resume also includes the CFO role at Biogen Idec BIIB . Merck's board is packed with current and retired CEOs, which can lead to quid pro quo compensation packages

  4. New Morningstar Analyst Report for Biogen Idec Inc

    Stock Reports

    Wed, 9 May 2012

    agreements between Biogen and partners Roche ..... collaboration with Roche. Biogen Idec markets novel MS ..... market share from Biogen 's products ..... right patients. Biogen Idec 's strategy has ..... addition, Roche and Biogen - Idec brought MS drug

  5. Why Billionaire Carl Icahn Could Target This Substantially Undervalued Biotech

    Headlines

    Tue, 8 May 2012

    have failed in taking over the board of Forest Laboratories ( FRX ), but this let down pales in comparison to his success at Biogen ( BIIB ) and Genzyme. Eli Lilly ( LLY ) is substantially undervalued and appears to many investors as a sinking ship. Moments like

  6. New Morningstar Analyst Report - Exelixis, Inc.

    Stock Reports

    Fri, 4 May 2012

    president of R&D at Exelixis) has replaced longtime CEO George Scangos, who left the company to take the reins at Biogen - Idec BIIB in 2010. As former president of biotechnology at Bayer BAYRY , Scangos was particularly well-suited to guide

  7. Biogen Idec's CEO Discusses Q1 2012 Results - Earnings Call Transcript

    Headlines

    Tue, 1 May 2012

    Biogen Idec ( BIIB ) Q1 2012 Earnings Call May 01, 2012 8:00 am ET Executives Wendy Gabel - George A. Scangos - Chief Executive Officer and Director

  8. Biogen Idec ( BIIB ): Q1 EPS of $1.40 misses by $0.09. Revenue of $1.29B (+7.4% Y/Y) misses by $20M. (PR)

    Headlines

    Tue, 1 May 2012

    Biogen Idec ( BIIB ): Q1 EPS of $1.40 misses by $0.09 . Revenue of $1.29B (+7.4% Y/Y) misses by $20M . ( PR ) Post your comment!

  9. Biogen Sees Mixed Results in the First Quarter, Slightly Raising Our FV Due to Cash Generation

    Commentary

    Tue, 1 May 2012

    Biogen - Idec BIIB reported first-quarter results that ..... this as a one-time event, and based on Biogen 's strong reported shipments through ..... as competition in the MS market (from Biogen and other drug firms) is growing. Tysabri

  10. Biogen Idec , Inc. BIIB Q1 2012 Earnings Call Transcript

    Headlines

    Tue, 1 May 2012

    At this time, I would like to welcome everyone to the Biogen Idec 's First Quarter 2012 Earnings Conference Call. All ..... question-and-answer session. Thank you and welcome to Biogen Idec 's first quarter 2012 earnings conference call. Before

« Prev12345Next »
Content Partners